An interventional study of IVL Pretreatment + OCT-Guided Stent Implantation and IVL Pretreatment + Angiography-Guided Stent Implantation in Coronary Artery Disease, Severe Coronary Artery Disease and Coronary Artery Calcification, sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd. (part of Blue Sail Medical Co., Ltd.) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. — 8 open to participants now, 11 under way, none of them phase 3. Coronary Artery Disease · Blue Sail Medical Co., Ltd..
Among the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., this one has the largest planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 16 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 23rd registered.
4,865 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →8 of the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:
Biosensors Europe SA · Sites in Malaysia
Ages 18+
JW Medical Systems Ltd · Sites in China
Ages 18+
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. · Sites in China
Ages 18–80
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. · Sites in China
Ages 18–80
JW Medical Systems Ltd
Ages 18–80
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 3,060 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 200 across the 16 interventional studies, 1,121 across the 7 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shanghai Bluesail Boyuan Medical Technology Co., Ltd., one of the names counted as Blue Sail Medical Co., Ltd.. Under that name alone:
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. is the lead sponsor of 7 studies on the registry; 7 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Severely calcified coronary artery disease means that calcium has built up in the blood vessels that supply the heart. This makes coronary procedures more difficult and increases the risk of complications during and after treatment.
The LOCATION Study is a large clinical study designed to compare different commonly used treatment strategies for patients with severely calcified coronary arteries who need a coronary stent. The study aims to find safer and more effective ways to prepare the artery and place the stent in order to improve long-term outcomes.
In this study, participants will be randomly assigned (like flipping a coin) to one of four treatment groups during their coronary procedure. The treatments differ in two ways: (1) how the calcified artery is prepared before placing the stent, and (2) how imaging is used to guide stent placement.
One method uses a shockwave-based device to help break calcium in the artery, while the other uses standard balloon treatment. For imaging guidance, one approach uses a high-resolution imaging catheter inside the artery, and the other relies on standard X-ray imaging. All participants will receive a standard, approved drug-eluting stent as part of routine care.
The main goal of the study is to determine which treatment approach best reduces serious heart-related problems over three years. These problems include heart-related death, heart attack in the treated vessel, or the need for another procedure on the same vessel.
Adults aged 18 years or older with significant coronary artery narrowing and severe calcium buildup may be eligible to participate. All participants must provide written informed consent before joining the study.
Participants will be followed during their hospital stay and through regular follow-up visits or phone calls for up to three years after the procedure. Information collected during the study will help doctors better understand how to treat patients with severely calcified coronary arteries in the future.
Participation in this study is voluntary, and patients may withdraw at any time without affecting their medical care. All study devices used in this trial are approved for clinical use, and patient privacy will be protected according to applicable regulations.
LOCATION Study is a prospective, multicenter, 2x2 factorial randomized controlled trial.
Number of Sites: Approximately 50 sites in China.
Trial Objectives:
Objective 1: To evaluate the efficacy and safety of coronary intravascular lithotripsy (IVL) compared with balloon angioplasty (BA) for pretreatment of severely coronary calcified lesions prior to implantation of stents.
Objective 2: To evaluate the efficacy of optical coherence tomography (OCT)-guided compared with angiography-guided stent implantation in severely coronary calcified lesions.
Trial Hypotheses:
Hypotheses 1: IVL pretreatment of severely calcified coronary artery lesions will reduce the 3-year risk of target vessel failure (TVF, a composite of cardiac death, target vessel myocardial infarction [TVMI], or clinically-driven target vessel revascularization [TVR]) compared with BA pretreatment.
Hypotheses 2: OCT-guided percutaneous coronary intervention (PCI) will reduce 3-year risk of TVF compared with angiography-guided PCI in severely coronary calcified lesions.
Trial Population:Patients with one or more angiographically severely calcified coronary lesions
Trial Devices:
IVL device: SoniCrackerTM Coronary IVL Therapy System (Shanghai Bluesail Boyuan Medical Technology co., Ltd) BA Devices: standard commercially approved balloon angioplasty devices including high-pressure balloons, scoring balloons, and cutting balloons, without brand restriction OCT device: Intravascular Imaging System (Nanjing Forssmann Medical Technology Co., Ltd)
Follow-up Visits:
Follow-up will range between 1-year minimum and 3-year maximum. Follow-up will be conducted at discharge, at 30 (±7) days, 180 (±7) days, at 1 year (±30 days), 2 years (±30 days), at 3 (±30 days) years with clinic visit or phone calls. When the last patient reaches 1 year follow-up, an additional "sweep visit" will be performed in all patients who have not had follow-up within 30 days. Additional visits will not be performed after this sweep visit.
Duration:The period of this trial is expected to be approximately 4 years.
Sample size Calculation:
This trial is expected to enroll 3,060 patients, and the sample size calculation is based on the cumulative incidence of TVF as the primary endpoint.
For Hypothesis 1: We expect that the rate of TVF in the BA group will be 7.0%, 12.5%, 16.0% at 1-year, 2-year, and 3-year follow-up, respectively. Assuming a 25% risk reduction, (i.e. the hazard ratio (HR) between the IVL group and the BA group is 0.75), it is estimated that the rate of TVF in the IVL group will be 5.3%, 9.4%, and 12.0% at 1-year, 2-year, and 3-year follow-up, respectively. The subject enrollment period is expected to be 3 years, with annual enrollment rates of 30%, 40%, and 30% respectively. Accounting for a 5% dropout rate in both groups, 3,060 total randomized patients provide 80% power to reject the null hypothesis at a two-sided α level of 0.05.
For Hypothesis 2: We expected that the rate of TVF in the angiography-guided group will be 7.7%, 13.8%, 17.6% at 1-year, 2-year, and 3-year follow-up, respectively. Assuming a 27% risk reduction (i.e. the HR between the OCT-guided group and the angiography-guided group is 0.73), the rate of TVF in the OCT-guided group will be 5.6%, 10.1%, and 12.9% at 1-year, 2-year, and 3-year follow-up, respectively. The subject enrollment period is expected to be 3 years, with annual enrollment rates of 30%, 40%, and 30% respectively. Accounting for a 5% dropout rate in both groups, 2,326 total randomized patients provide 80% power to reject the null hypothesis at a two-sided α level of 0.05. With 3,060 total subjects, 89.6% power is present to reject the null hypothesis.
No interaction between hypotheses 1 and 2 are expected; that is, the benefit of OCT guidance is expected to accrue to a similar degree after both IVL and BA pre-treatment of severely calcified lesions; as such, adjustment for multiplicity is not required. Thus, a total enrollment of 3,060 subjects is planned, with 1530 subjects in each group (IVL vs. BA vessel preparation, and OCT vs. angiography guidance).
Background:
Coronary artery disease (CAD) is a major cardiovascular disorder that imposes a substantial burden on global health. Percutaneous coronary intervention (PCI), as an effective therapeutic strategy for CAD, has been increasingly utilized in clinical practice. With the aging of the population, the proportion and severity of coronary artery calcified lesions have shown a progressive increase. Severely calcified lesions represent one of the most prevalent complex lesion subtypes in CAD that significantly increases the technical difficulty of coronary intervention and thus poses a major challenge to cardiovascular interventional physicians. Notably, patients with calcified lesions have a significantly higher incidence of perioperative complications and long-term major adverse cardiovascular events (MACE). [1] For the pretreatment of calcified lesions, specialized balloons are typically employed, including high-pressure non-compliant balloons, cutting balloons and scoring balloons, as well as coronary atherectomy. However, these approaches have certain limitations. For instance, coronary atherectomy modifies lesion compliance and enlarges the lumen through the ablation of calcified plaques; yet, it may increase the risk of distal embolization, which can result in slow flow or no-reflow. Additionally, its complexity impedes its widespread adoption. Meanwhile, cutting balloons and scoring balloons have not been proven to enhance clinical outcomes in severe calcification.
Coronary intravascular lithotripsy (IVL) is derived from urological lithotripsy techniques. The IVL system consists of miniaturized, arrayed lithotripsy emitters enclosed within a balloon that generate a localized field effect at calcified sites, thereby optimizing energy delivery for the treatment of coronary calcification. This process modifies vascular compliance while preserving the integrity of the native fibroelastic components of the vessel wall, thus reducing vascular injury. The DISRUPT CAD I trial (NCT02650128) [2], the first study investigating IVL, enrolled 60 patients and demonstrated a 98% device success rate for IVL. Following IVL, all patients underwent successful drug-eluting stent (DES) implantation. Subsequently, a series of prospective, multicenter studies have been conducted, including DISRUPT CAD II (NCT03328949) [3], DISRUPT CAD III (NCT03595176) [4-5], and Disrupt CAD IV (NCT04151628) [6-7]. These studies have demonstrated the efficacy and safety of IVL in the management of severe coronary calcified lesions.
The SoniCrackerTM Coronary Intravascular Lithotripsy Therapy System is an IVL product developed by Shanghai Bluesail Boyuan Medical Technology co., Ltd. The device has completed a prospective, multicenter, single-arm pre-market clinical study, enrolling a total of 184 patients with severe coronary artery calcification in China, which showed a procedural success rate of 96.7% (defined as a residual in-stent stenosis ≤30% following stent implantation and without in-hospital major adverse cardiac events). Angiographic success (defined as residual in-stent stenosis ≤30% following stent implantation and without serious angiographic complications) and device success (defined as the IVL catheter successfully crossing the target lesion and delivering lithotripsy without serious angiographic complications) rates were both 100%, with no cases of post-stent residual stenosis >30% or severe angiographic complications. No intraoperative MACE occurred, and the postoperative 6-month MACE rate was 4.9%. The target lesion failure (TLF) rates at 1 month and 6 months post-procedure were 3.3% and 4.4%, respectively. Optical coherence tomography (OCT) subgroup analysis showed immediate post-procedure minimum stent area of 5.30±1.74 mm², minimum stent lumen diameter of 2.56±0.42 mm, immediate lumen gain diameter of 0.98±0.57 mm, and immediate lumen gain area of 3.29±1.45 mm² (data not published). The trial confirmed the device's favorable safety and efficacy. However, there is currently a lack of randomized controlled clinical trial data comparing IVL technology with other calcified lesion management strategies to further validate the superiority of IVL.
Current guidelines recommend the use of intravascular imaging guidance during PCI for complex coronary lesions (especially left main, true bifurcation, and long lesions). However, there remains a lack of intravascular imaging-guided studies with sufficient statistical power to confirm its efficacy in severely calcified lesions. Common clinical intravascular imaging modalities primarily include intravascular ultrasound (IVUS) and OCT. Compared to IVUS, OCT offers distinct advantages in evaluating calcified lesions: it can precisely assess calcification thickness and more accurately quantify the volume of calcified lesions, which is of great significance for determining optimal treatment strategies. Therefore, this trial is designed to evaluate the clinical benefits of OCT-guided stent implantation specifically in severe coronary calcified lesions.
The present clinical trial will employ the SoniCracker™ Coronary Intravascular Lithotripsy Therapy System and Intravascular Imaging System (Nanjing Forssmann Medical Technology Co., Ltd) to further evaluate two key aspects: first, the efficacy and safety of IVL using the SoniCracker™ system versus balloon angioplasty as pretreatment for severely coronary calcified lesions prior to stent implantation; second, the efficacy and safety of OCT-guided versus angiography-guided stent implantation in severely coronary calcified lesions.
Analysis of Potential Benefits
The devices used in the trial have demonstrated safety and efficacy in pre-market clinical trials and has obtained marketing approval from the China National Medical Products Administration (NMPA). Potential benefits include: achieving immediate procedural success, adequate stent expansion, reducing intraoperative complications, improving long-term vascular patency, and clinical outcomes, etc. Participation in this trial is purely voluntary, and enrolled subjects will not receive direct additional benefits. However, information collected from this trial may help deepen the understanding of clinical outcomes in percutaneous coronary intervention (PCI). Ultimately, this knowledge may provide physicians with more information to help improve the treatment of future patients.
Data Management System
The data collection/management system for this trial is an EDC (Electronic Data Capture) system. This is a validated electronic data capture system with audit trial management and user permission management capabilities.
Source data verification is performed to ensure the accuracy and completeness of key study variables. Protocol deviations, adverse events, and serious adverse events are documented and reported according to the study protocol and applicable regulatory and local regulatory requirements.
General Principles
Continuous variables will be summarized as the number of observations, number of missing values, mean, standard deviation, median, quartiles, and range. Categorical variables will be summarized as the number of observations, number of missing values, frequencies, and percentages. Baseline clinical, demographic, laboratory and procedural characteristics will be summarized by randomized treatment group.
All statistical analyses will be performed using SAS software, Version 9.4 or greater. For comparison between the two groups, all hypothesis tests are conducted by two-sided test, α=0.05. The efficacy analysis will be conducted according to the intention-to-treat (ITT) principle. Kaplan-Meier curves and log-rank test will be used to analyze and compare the timing of the first event in each group. P \<0.05 is statistically significant. The reliability of all 2-sided confidence intervals (CI) is 95%, and Cox proportional risk regression model is used to determine the hazard ratio (HR).
Ethical Considerations
The study is conducted in compliance with the Declaration of Helsinki, applicable regulatory requirements, and approvals from institutional review boards or ethics committees at each participating site. All participants provide written informed consent prior to enrollment. Participant confidentiality is maintained throughout the study.
The Clinical Events Committee (CEC) will be established for this study.The Crossover Device Evaluation Committee will be established to provide impartial assessment of crossover subjects.The imaging core lab(s) will provide central reading/analysis for angiographic and OCT images generated pre-procedure,during the procedure, and post-procedure at enrolling sites.
Data Safety Monitoring Board (DSMB)
A Data Safety Monitoring Board will be established for this clinical trial to assess, at intervals during the trial, the data and to recommend to the Steering Committee whether to continue, suspend, modify, or terminate the trial early. The DSMB will consist of a minimum of three (3) members, one of which will be a statistician. The DSMB will not be affiliated with the Sponsor or its members will not be actively participating in the trial. Details of the DSMB's composition, specific review processes, and operating procedures are outlined in its charter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical Inclusion criteria:
Subject presents with:
Angiographic inclusion criteria:
<!-- -->
A stenosis of the target lesion ≥50% and \<70% (visual estimation) with evidence of ischemia via:
Pressure wire FFR or angioFFR value ≤0.80 or instantaneous wave-free ratio (iFR) value ≤0.89.
3.The target lesion has fluoroscopic evidence of severe calcium at the lesion site, defined via angiogram as fluoroscopic radiopacities noted without cardiac motion before contrast injection involving both sides of the arterial wall in at least 1 location and total length of calcium of at least 15 mm; All lesions in the non-target vessel, if any, that require treatment are successfully treated without complications prior to randomization, defined as final diameter stenosis ≤20% with final TIMI-3 flow, with no residual dissection grade ≥type B, and no transient or sustained angiographic complications (e.g. distal embolization, side branch closure), no chest pain lasting >5 minutes, and no ST-segment elevation or depression lasting >5 minutes.
Exclusion Criteria:
Clinical exclusion criteria:
<!-- -->
Angiographic Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(1st OCT) perform OCT after the small balloon pre-dilatation but before the IVL; then IVL is performed\* followed by the 1:1 high-pressure balloon pre-dilatation followed by the 2nd OCT; then implant the DES and perform post-dilatation with a high-pressure balloon at ≥18 atm (mandatory); then perform the final OCT (3rd OCT). Assess the stent to determine if further PCI is required to optimize stent implantation - either maximize stent expansion or treat malapposition, tissue protrusion, a major edge dissection or untreated reference segment disease. If further stent optimization is required, do so, after which a final OCT run must be performed again (4th OCT). Note: If IVL is unable to cross or dilate the lesion, rotational atherectomy, orbital atherectomy, or excimer laser should be performed followed by IVL. OCT must still be performed prior to stenting. Investigators should use IVL in accordance with the device's instructions for use.
Device: IVL Pretreatment + OCT-Guided Stent Implantation
An attempt should be made to cross the target lesion with the IVL catheter after the 1.5 mm or 2.0 mm balloon dilation. If the IVL will not cross the lesion, a larger balloon or atherectomy may be used - then IVL must be performed\*. Following successful IVL, pre-dilatation must be performed and be successful (complete balloon expansion) with a high-pressure balloon sized 1:1 to the distal reference segment prior to stenting (mandatory); then one or more stents are implanted (DES only); then post-dilatation must be performed with a high-pressure balloon at ≥18 atm (mandatory). A final OCT run blinded to the operator is then performed as the last procedure. NOTE: Investigators should use IVL in accordance with the device's instructions for use.
Device: IVL Pretreatment + Angiography-Guided Stent Implantation
(1st OCT) perform baseline OCT after the 1.5 or 2.0 mm balloon; then perform balloon pre-dilatation with a high-pressure balloon sized 1:1 to the distal RVD\*; then perform OCT again (2nd OCT); then implant the DES and perform post-dilatation with a high-pressure balloon at ≥18 atm (mandatory); then perform the final OCT (3rd OCT). Assess the stent to determine if further PCI is required to optimize stent implantation - either maximize stent expansion or treat malapposition, tissue protrusion, a major edge dissection or untreated reference segment disease. If further stent optimization is required, do so, after which a final OCT run must be performed again (4th OCT).
Device: Balloon Angioplasty (BA) Pretreatment + OCT-Guided Stent Implantation
pre-dilatation must be successful (complete balloon expansion) with a high-pressure balloon (or scoring balloon, cutting balloon, etc.) sized 1:1 to the distal reference segment (mandatory)\*; then one or more stents are implanted (DES only); then post-dilatation must be performed with a high-pressure balloon at ≥18 atm (mandatory). \*Note: if the 1:1 pre-dilatation balloon is unable to be fully expanded, rotational atherectomy, orbital atherectomy, or excimer laser may be performed. Crossover to IVL is not allowed. After atherectomy or excimer laser, the lesion must again be successfully pre-dilated (complete balloon expansion) with a high-pressure balloon sized 1:1 to the distal reference segment (mandatory) prior to stenting. A final OCT run blinded to the operator is then performed as the last procedure;
Device: Balloon Angioplasty (BA) Pretreatment + Angiography-Guided Stent Implantation
Subjects who have signed ICF and have met all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 to IVL vessel preparation strategy or balloon angioplasty vessel preparation strategy. Concurrently, subjects will randomly be assigned in a 1:1 ratio to receive OCT-guidance or angiographic-guidance of the PCI procedure. Subject randomization in each of the 4 groups will be stratified by site and diabetes in varying block sizes of 2, 4 or 6. Randomization will be conducted with the use of an interactive web response system (IWRS).
Subjects who have signed ICF and have met all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 to IVL vessel preparation strategy or balloon angioplasty vessel preparation strategy. Concurrently, subjects will randomly be assigned in a 1:1 ratio to receive OCT-guidance or angiographic-guidance of the PCI procedure. Subject randomization in each of the 4 groups will be stratified by site and diabetes in varying block sizes of 2, 4 or 6. Randomization will be conducted with the use of an interactive web response system (IWRS).
Subjects who have signed ICF and have met all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 to IVL vessel preparation strategy or balloon angioplasty vessel preparation strategy. Concurrently, subjects will randomly be assigned in a 1:1 ratio to receive OCT-guidance or angiographic-guidance of the PCI procedure. Subject randomization in each of the 4 groups will be stratified by site and diabetes in varying block sizes of 2, 4 or 6. Randomization will be conducted with the use of an interactive web response system (IWRS).
Subjects who have signed ICF and have met all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 to IVL vessel preparation strategy or balloon angioplasty vessel preparation strategy. Concurrently, subjects will randomly be assigned in a 1:1 ratio to receive OCT-guidance or angiographic-guidance of the PCI procedure. Subject randomization in each of the 4 groups will be stratified by site and diabetes in varying block sizes of 2, 4 or 6. Randomization will be conducted with the use of an interactive web response system (IWRS).
Target Vessel Failure (TVF) at 3 years
Composite time-to-first event rate of cardiac death, target vessel myocardial infarction (TV-MI), or ischemia-driven target vessel revascularization (iTVR) at 3 years, assessed when the last enrolled patient reaches 1-year follow-up
Time frame: 3 years
TVF (Target Vessel Failure )(at 1 and 2 years)
Time frame: 1 and 2 years
Target Lesion Failure (TLF)
defined as composite of cardiac death, TVMI, or ischemia-driven target lesion revascularization (iTLR); 3.Major Adverse Cardiovascular Events (MACE), defined as cardiac death, all MI, or TVR;
Time frame: 30 days, 6 months ,1 year, 2 years, and 3 years
Major Adverse Cardiovascular Events (MACE)
defined as cardiac death, all MI, or TVR;
Time frame: 30 days, 6 months,1 year, 2 years, and 3 years
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
including all-cause death, MI, stroke, or any revascularization;
Time frame: 30 days, 6 months,1 year, 2 years, and 3 years
Cardiac death
Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all cardiac procedure related deaths including those related to concomitant treatment.
Time frame: 30 days, 6 months,1 year, 2 years, and 3 years
Incidence of stent thrombosis
definite or probable stent thrombosis according to the Academic Research Consortium (ARC) criteria.
Time frame: 30 days, 6 months,1 year, 2 years, and 3 years
Severe angiographic complications
including type D-F dissection (NHLBI classification), vascular perforation, acute vessel occlusion, persistent slow flow or persistent no-reflow during the procedure;
Time frame: Immediate post-procedure
Procedural strategy success
defined as successful passage of the randomized study device through the target lesion, successful study device balloon expansion, successful stent placement with residual stenosis ≤20%, and no occurrence of MACE during hospitalization; Note: Small balloons for pre-dilatation are permitted in the IVL arm. Crossovers to any device (rotational atherectomy, orbital atherectomy, excimer laser, high-pressure, or cutting/scoring balloons) in the IVL arm are defined as a failure. Crossovers to IVL in the BA arm are not permitted but if used (protocol violation), this is a procedural failure. If rotational atherectomy, orbital atherectomy, or excimer laser are required for study device delivery in BA arm, this is also defined as a procedural failure.
Time frame: Immediate post-procedure
Post-procedural minimum stent area (MSA) at the site of maximum calcification and across the entire target lesion;
Time frame: Immediate post-procedure
Post-procedural mean stent area
Time frame: Immediate post-procedure
Post-procedural minimum lumen diameter (MLD)
MLD refers to the minimum lumen diameter within the stent post-procedure.
Time frame: Immediate post-procedure
Minimum stent expansion
Minimum stent expansion is the minimum lumen area within the stent divided by the average of proximal and distal reference lumen areas x 100
Time frame: Immediate post-procedure
Stent malposition
defined as distance from stent struts to the vessel wall ≥0.4 mm and the length of stent malposition ≥1 mm;
Time frame: Immediate post-procedure
Number of calcification fractures
Time frame: Immediate post-procedure
Major and minor edge dissection
Edge dissection is classified as major if it involves ≥60 degrees of the vessel circumference at the dissection site and measures ≥3 mm in length or as minor if there is any visible edge dissection involving \<60 degrees of the vessel circumference or \<3 mm in length;
Time frame: Immediate post-procedure
Major and minor tissue protrusion
Tissue protrusion is classified as major if the protrusion area/stent area at the site of tissue protrusion is ≥10% and the minimal intrastent flow area is \<90% of the proximal or distal reference area. Note, the minimum in-stent flow area is the minimum value compared with the difference between the stent area and the prolapse area. Tissue protrusion is classified as minor if the protrusion area/stent area at the site of tissue protrusion is \<10%, or is ≥10% but the minimal intraluminal flow area is ≥90% of proximal or distal reference area;
Time frame: Immediate post-procedure
Incidence of Untreated reference segment disease
Untreated reference segment disease is defined as focal disease with an untreated minimal lumen area (MLA) \<4.5 mm2 within 5 mm from the proximal and/or distal stent edges.
Time frame: Immediate post-procedure
Target vessel myocardial infarction (TV-MI)
consists of periprocedural MI and spontaneous MI that arise from the target vessel., spontaneous MI using the 4th UDMI, peri-procedural MI using SCAI
Time frame: 30 days, 6 months,1 year, 2 years, and 3 years
ischemia-driven target vessel revascularization (iTVR)
repeat revascularization of the target vessel with ischemic symptoms and angiographic evidence
Time frame: 30 days, 6 months,1 year, 2 years, and 3 years
MI (Myocardial Infarction)
consists of periprocedural MI and spontaneous MI, spontaneous MI using the 4th UDMI, peri-procedural MI using SCAI target vessel revascularization, Repeat revascularization of the target vessel
Time frame: 30 days, 6 months,1 year, 2 years, and 3 years
all-cause death
Time frame: 30 days, 6 months,1 year, 2 years, and 3 years
Stoke
Time frame: 30 days, 6 months,1 year, 2 years, and 3 years
any revascularization
Time frame: 30 days, 6 months,1 year, 2 years, and 3 years
Post-procedural mean lumen diameter(LD)
LD refers to the average value of lumen diameter measurements calculated by averaging data from all cross-sections throughout the stent
Time frame: Immediate post-procedure
Mean stent expansion
Mean stent expansion is the mean stent area (stent volume/analysed stent length) divided by the average of proximal and distal reference lumen areas x 100
Time frame: Immediate post-procedure
Thickness (full-layer or partial) of calcification (mm)
Time frame: Immediate post-procedure
Depth of calcification fractures(mm)
Time frame: Immediate post-procedure
Plan to share: No — This study has no plan to share de-identified individual participant data (IPD) with researchers outside the primary study team. The reasons for this decision are as follows: Informed Consent \& Ethical Commitment: The informed consent documents for this study do not include provisions for IPD sharing, as participants only consented to data use for the original analysis of this study. This approach has been reviewed and approved by the Institutional Review Board/Ethics Committee (IRB/IEC) to uphold ethical commitments and avoid using data beyond the scope of participant understanding.
Start is estimated for Mar 2026; primary completion for Jan 2030, 46 months later.
Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 46 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. →